Friday, April 30, 2010
Push for progress on pancreatic cancer
Push for progress on pancreatic cancer
You won't see it on a billboard or targeted in a police blitz, but you're more likely to die of pancreatic cancer in Australia than from a road accident.
Pancreatic cancer claims five Australian lives every day as one of the nation's most lethal diseases and yet it has remained off the health radar - in part, because of the grim prognosis of sufferers and no significant development in treatment.
"Despite considerable research efforts into pancreatic cancer over the last decade, very little progress has been made in the treatment of this disease," says Professor David Goldstein, a medical oncologist and director of the Sydney-based GI CANCER Institute.
Posted using ShareThis
You won't see it on a billboard or targeted in a police blitz, but you're more likely to die of pancreatic cancer in Australia than from a road accident.
Pancreatic cancer claims five Australian lives every day as one of the nation's most lethal diseases and yet it has remained off the health radar - in part, because of the grim prognosis of sufferers and no significant development in treatment.
"Despite considerable research efforts into pancreatic cancer over the last decade, very little progress has been made in the treatment of this disease," says Professor David Goldstein, a medical oncologist and director of the Sydney-based GI CANCER Institute.
Posted using ShareThis
Wednesday, April 28, 2010
Molecular marker could help spot pancreatic cancer early
Molecular marker could help spot pancreatic cancer early
CHAPEL HILL – Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a molecular marker of pancreatic cancer that may help spot the disease at its earliest stages, when it can be treated more successfully with surgery.
In a finding published April 26, 2010, in the online journal PLoS One, the researchers showed that a specific form of a protein called palladin is produced in large amounts in the "tumor nest," the cells that surround a pancreatic tumor.
By measuring the levels of this form of palladin in patient samples, doctors could have an improved way to screen for the deadly cancer, possibly catching it earlier than ever before, said senior study author Carol Otey, Ph.D., associate professor of cell and molecular physiology at UNC.
Otey is a member of the NC Translational and Clinical Sciences Institute (NC TRaCS), part of a collaborative effort of a national network of medical research institutions affiliated with the NIH Clinical and Translational Science Awards (CTSAs).
"The problem with pancreas cancer is it is almost never caught at an early stage," said Otey. "By the time a person develops suspicious symptoms, the disease has typically progressed too far. But if you can diagnose it early, it can be treated very effectively with surgery."
CHAPEL HILL – Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a molecular marker of pancreatic cancer that may help spot the disease at its earliest stages, when it can be treated more successfully with surgery.
In a finding published April 26, 2010, in the online journal PLoS One, the researchers showed that a specific form of a protein called palladin is produced in large amounts in the "tumor nest," the cells that surround a pancreatic tumor.
By measuring the levels of this form of palladin in patient samples, doctors could have an improved way to screen for the deadly cancer, possibly catching it earlier than ever before, said senior study author Carol Otey, Ph.D., associate professor of cell and molecular physiology at UNC.
Otey is a member of the NC Translational and Clinical Sciences Institute (NC TRaCS), part of a collaborative effort of a national network of medical research institutions affiliated with the NIH Clinical and Translational Science Awards (CTSAs).
"The problem with pancreas cancer is it is almost never caught at an early stage," said Otey. "By the time a person develops suspicious symptoms, the disease has typically progressed too far. But if you can diagnose it early, it can be treated very effectively with surgery."
Sunday, April 25, 2010
What Are The Risk Factors For Pancreatic Cancer? | Health Tips
What Are The Risk Factors For Pancreatic Cancer? | Health Tips
Pancreatic cancer is currently the fifth most common form of cancer in the United States and is diagnosed in around 40,000 Americans each year. In most cases pancreatic cancer has an extremely poor survival outcome. Just 1 in 20 people diagnosed with pancreatic cancer will still be alive after five years.
The main reason pancreatic cancer has such a poor survival outcome is that the majority of cases are diagnosed when the cancer is at a very late stage. This is due to the non-specific symptoms associated with pancreatic cancer in its early stages. Early warning signs of pancreatic cancer include pain in the upper abdomen, jaundice, loss of appetite, and weight loss.
There are several risk factors that are known to affect an individuals probability of developing pancreatic cancer. While some of these cannot be changed, several can be influenced by sensible lifestyle and diet modifications.
Here are eleven of the more established risk factors for pancreatic cancer.
Posted using ShareThis
Pancreatic cancer is currently the fifth most common form of cancer in the United States and is diagnosed in around 40,000 Americans each year. In most cases pancreatic cancer has an extremely poor survival outcome. Just 1 in 20 people diagnosed with pancreatic cancer will still be alive after five years.
The main reason pancreatic cancer has such a poor survival outcome is that the majority of cases are diagnosed when the cancer is at a very late stage. This is due to the non-specific symptoms associated with pancreatic cancer in its early stages. Early warning signs of pancreatic cancer include pain in the upper abdomen, jaundice, loss of appetite, and weight loss.
There are several risk factors that are known to affect an individuals probability of developing pancreatic cancer. While some of these cannot be changed, several can be influenced by sensible lifestyle and diet modifications.
Here are eleven of the more established risk factors for pancreatic cancer.
Posted using ShareThis
Saturday, April 24, 2010
Wednesday, April 21, 2010
Immunomedics Reports New Blood Test for Detecting Early Stage Pancreatic Cancer Correlates With Response to Clivatuzumab Tetraxetan Treatment - MarketWatch
Immunomedics Reports New Blood Test for Detecting Early Stage Pancreatic Cancer Correlates With Response to Clivatuzumab Tetraxetan Treatment - MarketWatch
Immunomedics, Inc. /quotes/comstock/15*!immu/quotes/nls/immu (IMMU 3.72, 0.00, 0.00%) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.
Posted using ShareThis
Immunomedics, Inc. /quotes/comstock/15*!immu/quotes/nls/immu (IMMU 3.72, 0.00, 0.00%) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.
Posted using ShareThis
Tuesday, April 13, 2010
Immunomedics to Report on Potential Cancer Therapy Products in 8 Presentations at 101st Annual AACR Meeting - MarketWatch
Immunomedics to Report on Potential Cancer Therapy Products in 8 Presentations at 101st Annual AACR Meeting - MarketWatch
MORRIS PLAINS, N.J., Apr 12, 2010 (GlobeNewswire via COMTEX) -- Immunomedics, Inc. /quotes/comstock/15*!immu/quotes/nls/immu (IMMU 3.69, +0.12, +3.36%) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research (AACR), April 17 -- 21, 2010, in Washington, DC.
The spotlight of this year's presentations will be on pancreatic cancer, highlighted by a study correlating the results from a blood test for pancreatic cancer detection with responses to a radiolabeled antibody therapy. Additionally, the Company will introduce new antibody-drug conjugates (ADC) being studied in this cancer. (Please refer to the Company's press release at www.immunomedics.com/news_pdf/2010_PDF/PR01212010.pdf for more information on the new blood test).
Posted using ShareThis
MORRIS PLAINS, N.J., Apr 12, 2010 (GlobeNewswire via COMTEX) -- Immunomedics, Inc. /quotes/comstock/15*!immu/quotes/nls/immu (IMMU 3.69, +0.12, +3.36%) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research (AACR), April 17 -- 21, 2010, in Washington, DC.
The spotlight of this year's presentations will be on pancreatic cancer, highlighted by a study correlating the results from a blood test for pancreatic cancer detection with responses to a radiolabeled antibody therapy. Additionally, the Company will introduce new antibody-drug conjugates (ADC) being studied in this cancer. (Please refer to the Company's press release at www.immunomedics.com/news_pdf/2010_PDF/PR01212010.pdf for more information on the new blood test).
Posted using ShareThis
Saturday, April 10, 2010
Studies Show Soda Linked to Pancreatic Cancer
Studies Show Soda Linked to Pancreatic Cancer
A new study has found a new negative thing related to sodas. Researchers at the University of Minnesota’s School of Public Health decided to cull through data from the Singapore Chinese Health Study, assessing whether sugar-sweetened soft drinks and juices had a noticeable effect in a different population. They concluded: yes on soft drinks, no on juices. In fact, consumption of two or more soft drinks a week was linked to an 87% increase in the risk of pancreatic cancer.
A new study has found a new negative thing related to sodas. Researchers at the University of Minnesota’s School of Public Health decided to cull through data from the Singapore Chinese Health Study, assessing whether sugar-sweetened soft drinks and juices had a noticeable effect in a different population. They concluded: yes on soft drinks, no on juices. In fact, consumption of two or more soft drinks a week was linked to an 87% increase in the risk of pancreatic cancer.
Friday, April 9, 2010
Early diagnosis remains key for those who treat cancer patients | West Central Tribune | Willmar, Minnesota
Early diagnosis remains key for those who treat cancer patients | West Central Tribune | Willmar, Minnesota
If the outlook for pancreatic and liver cancer is to improve, earlier diagnosis needs to be one of the main strategies, say physicians who treat these patients.
“That’s where we can do some major changes in survival and life expectancy,” said Dr. Ahsan Bhatti, a gastroenterologist at Affiliated Community Medical Centers in Willmar.
How to manage these two formidable cancers was the focus this week of the annual cancer symposium, hosted by the Willmar Regional Cancer Center.
Posted using ShareThis
If the outlook for pancreatic and liver cancer is to improve, earlier diagnosis needs to be one of the main strategies, say physicians who treat these patients.
“That’s where we can do some major changes in survival and life expectancy,” said Dr. Ahsan Bhatti, a gastroenterologist at Affiliated Community Medical Centers in Willmar.
How to manage these two formidable cancers was the focus this week of the annual cancer symposium, hosted by the Willmar Regional Cancer Center.
Posted using ShareThis
Tuesday, April 6, 2010
Pancreatic cancer - Wikipedia, the free encyclopedia
Pancreatic cancer - Wikipedia, the free encyclopedia
Pancreatic cancer is a malignant neoplasm of the pancreas. Each year in the United States, about 42,470 individuals are diagnosed with this condition and 35,240 die from the disease.[1] The prognosis is relatively poor but has improved; the three-year survival rate is now about thirty percent, but less than 5 percent of those diagnosed are still alive five years after diagnosis. Complete remission is still rather rare.[2]
About 95% of exocrine pancreatic cancers are adenocarcinomas (M8140/3). The remaining 5% include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with osteoclast-like giant cells.[3] Exocrine pancreatic cancers are far more common than endocrine pancreatic cancers (also known as islet cell carcinomas), which make up about 1% of total cases.[4][5]
Posted using ShareThis
Pancreatic cancer is a malignant neoplasm of the pancreas. Each year in the United States, about 42,470 individuals are diagnosed with this condition and 35,240 die from the disease.[1] The prognosis is relatively poor but has improved; the three-year survival rate is now about thirty percent, but less than 5 percent of those diagnosed are still alive five years after diagnosis. Complete remission is still rather rare.[2]
About 95% of exocrine pancreatic cancers are adenocarcinomas (M8140/3). The remaining 5% include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with osteoclast-like giant cells.[3] Exocrine pancreatic cancers are far more common than endocrine pancreatic cancers (also known as islet cell carcinomas), which make up about 1% of total cases.[4][5]
Posted using ShareThis
Subscribe to:
Posts (Atom)